UNSPSC 51162419: Phenylephrine/phenylpropanolamine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE200. This VA Drug Class (RE200) classifies this compound as belonging to the group DECONGESTANTS, SYSTEMIC.

UNSPSC 51162419 Phenylephrine/phenylpropanolamine/pseudoephedrine is a Commodity code representing decongestant and sympathomimetic pharmaceutical ingredients and products. Recent state and local solicitations under this code show procurement of naloxone and drug deactivation systems rather than the narrow pharmaceutical actives the code nominally names, suggesting a mismatch between the code's technical scope and actual buying patterns. State and local governments acquire these products through both direct county health procurement and multi-state cooperative purchasing arrangements. The issuing bodies include county health departments and state-administered cooperative alliances that aggregate demand across multiple jurisdictions and participating states. Vendors typically must comply with federal drug manufacturing standards (cGMP, DSCSA), maintain relationships with authorized pharmaceutical wholesalers, and demonstrate pricing flexibility through negotiated pricing models.

Recent activity spans Florida and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2026 response deadline, awarded on a fixed-fee basis with a two-year initial term and one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026; MMCAP contracts with three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and weighs pricing at 75 percent of the evaluation score. The code shows limited recent relevant activity; opportunities posted under it often reflect downstream product categories rather than the pharmaceutical actives themselves.